ZIOPHARM Oncology, Inc Logo Image

ZIOPHARM Oncology, Inc

ZIOPHARM Oncology, Inc Banner Image

Most Recent Annual Report

2019 Annual Report and Form 10K

ZIOPHARM Oncology, Inc

ZIOPHARM Oncology, Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About ZIOPHARM Oncology, Inc

51-200 Employees
Based in Boston, Massachusetts

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the development and commercialization of in-licensed cancer drugs in North America. The company’s products under various clinical programs include Palifosfamide for the treatment of sarcoma, testicular cancer, head and neck cancer, lymphomas, and other solid tumors; Darinaparsin, an anti-mitochondrial compound for the treatment of acute promyelocytic leukemia, a precancerous condition; and Indibulin, a novel orally available small molecular-weight inhibitor of tubulin polymerization, as well as develops novel DNA-based biotherapeutics.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol